Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 2—February 2016
Dispatch

Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England

Shamez LadhaniComments to Author , Marzia Monica Giuliani, Alessia Biolchi, Mariagrazia Pizza, Kazim Beebeejaun, Jay Lucidarme, Jamie Findlow, Mary Ramsay, and Ray Borrow
Author affiliations: St. George’s University of London Paediatric Infectious Diseases Research Group, London, UK (S.N. Ladhani); Public Health England, London (S.N. Ladhani, K. Beebeejaun, M.E. Ramsay); GSK Vaccines, Siena, Italy (M.M. Giuliani, A. Biolchi, M. Pizza); Public Health England, Manchester, UK (J. Lucidarme, J. Findlow, R. Borrow)

Main Article

Table

Bactericidal antibody titers in pooled serum samples from infants vaccinated with Bexsero and adolescents immunized with Menveo against 6 invasive clinical Neisseria meningitidis serogroup W isolates in England and Wales, UK, during 2011–2012*

Isolate Adolescents receiving Menveo
Infants receiving Bexsero
Positive control†
Negative control‡ Pool 1§ Pool 2¶ Pool 3# Pool 4**
Before After
M11–240417 <16 256 <2 64 128 >128 >128
M11–240427 <16 128 <2 32 32 64 64
M11–240802 <16 512 <2 32 >64 >64 >64
M12–240016 <16 256 <2 32 32 64 128
M11–240798 <16 512 <2 >64 >64 >64 >64
M12–240754 <16 256 <2 64 64 >64 >64

*Human serum bactericidal antibody titers against 6 meningococcal group W clinical isolates belonging to ST-11 clonal complex using pooled serum from adolescents immunized with the MenACWY conjugate vaccine, Menveo, and from infants immunized with the protein-based, multicomponent meningococcal vaccine, Bexsero.
†Pooled serum samples from adolescents 11–17 years of age before and 1 month after receiving a single dose of MenACWY (Menveo) conjugate vaccine (n = 10).
‡Pooled prevaccination serum samples from infants at 2 months of age (n = 180) (control).
§Pooled serum samples from infants who received 3 doses of vaccine at 2, 3, and 4 months of age and had a blood sample taken 1 month after the last dose of vaccine (n = 56).
¶Pooled serum samples from infants who received 3 doses of vaccine at 2, 4, and 6 months of age and had a blood sample taken 1 month after the last dose of vaccine (n = 47).
#Pooled serum samples from infants who received 3 doses of vaccine at 2, 4, and 6 months of age plus a booster at 12 months and had a blood sample taken 1 month after the booster (n = 72).
**Pooled serum samples from an additional cohort of infants who also received 3 doses of vaccine at 2, 4, and 6 months of age plus a booster at 12 months and had a blood sample taken 1 month after the booster (n = 94).

Main Article

Page created: January 15, 2016
Page updated: January 15, 2016
Page reviewed: January 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external